Edgar Filing: Spiegel Robert J. - Form 4

Spiegel Rob	ert J.								
Form 4 September 1	0. 2018								
							OMB APPROVAL		
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						3235-0287		
Check th if no long subject to Section 1 Form 4 o Form 5 obligatio may cont <i>See</i> Instru 1(b).	ger 5 16. 5 5 5 5 5 5 5 5 5 5 5 5 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940					January 31, Expires: 2005 Estimated average burden hours per response 0.5		
(Print or Type I	Responses)								
Spiegel Robert J. S			suer Name and Ticko ol acel Pharmaceuti CC]	-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		(Mont 09/06 C.,, 200	e of Earliest Transac h/Day/Year) 5/2018	tion	X Director Officer (giv below)		% Owner her (specify		
			mendment, Date Ori Month/Day/Year)	ginal	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BERKELE	Y HEIGHTS,, NJ	07922				More than One R			
(City)	(State)	(Zip) T	able I - Non-Deriva	tive Securities	Acquired, Disposed	of, or Beneficia	lly Owned		
(Instr. 3) any (Month/Day/Year)		f TransactionAcqu Code Dispo) (Instr. 8) (Instr	TransactionAcquired (A) or Code Disposed of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Rep	port on a separate line	e for each class of s	ecurities beneficially	owned directly	or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Spiegel Robert J. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				Securities 4)	8. D S (I
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.43	09/06/2018		А	8,576	09/06/2019	09/06/2028	Common Stock	8,576	

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
Spiegel Robert J. C/O CYCLACEL PHARM 200 CONNELL DRIVE, S BERKELEY HEIGHTS,, N	Х					
Signatures						
/s/ Robert J. Spiegel	09/10/2018					
<u>**</u> Signature of	Date					

Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v). *

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.